Bryant Furlow

Bryant Furlow is medical journalist working at the crossroads of research, clinical practice, and public policy. His work has appeared The Lancet, New Scientist, and Oncology Nurse Advisor.

Most Recent Articles by Bryant Furlow

Are Liquid Biopsies Trustworthy?

Are Liquid Biopsies Trustworthy?

By

A study could not determine whether one liquid biopsy panel is more accurate than another overall.

Emerging Therapies for Prostate Cancer

Emerging Therapies for Prostate Cancer

By

New diagnostic and therapeutic tools are in development to inform the management of advanced and metastatic disease.

Chronic Myeloid Leukemia: Choosing A TKI

Chronic Myeloid Leukemia: Choosing A TKI

By

Clinical trial data regarding deep molecular response outcomes suggest that dasatinib and nilotinib are superior to the first-generation TKI, imatinib.

Prostate Cancer: Hypofractionated Radiotherapy's Role in Post-operative Settings

Prostate Cancer: Hypofractionated Radiotherapy's Role in Post-operative Settings

By

Hypofractionated radiotherapy's role in postoperative settings remains unclear and awaits outcomes from ongoing studies.

Reasons for MGUS Progression to Myeloma Remain Unclear

Reasons for MGUS Progression to Myeloma Remain Unclear

By

Studying how MGUS and myeloma clones change over time might yield new insights into myeloma's molecular heterogeneity.

More Articles by Bryant Furlow

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs